As a model radio-photodynamic therapy (RPDT) agent, we developed a multicomponent nanomaterial by anchoring conjugated chromophores on the surface of scintillating chrysotile nanotubes. Its ultimate composition makes the system a scintillation-activated photosensitizer for the singlet oxygen production. This nanomaterial shows a remarkable ability to enhance the production of singlet oxygen in an aqueous environment, under X-ray irradiation, boosting its production by almost 1 order of magnitude. Its efficiency as a coadjutant for radiotherapy has been tested in vitro, showing a striking efficacy in enhancing both the prompt cytotoxicity of the ionizing radiation and the long-term cytotoxicity given by radiation-activated apoptosis. Notably, the beneficial activity of the RPDT agent is prominent at low levels of delivered doses comparable to the one employed in clinical treatments. This opens the possibility of effectively reducing the therapy exposure and consequently undesired collateral effects due to prolonged exposure of patients to high-energy radiation.
Villa, I., Villa, C., Crapanzano, R., Secchi, V., Tawfilas, M., Trombetta, E., et al. (2021). Functionalized Scintillating Nanotubes for Simultaneous Radio- and Photodynamic Therapy of Cancer. ACS APPLIED MATERIALS & INTERFACES, 13(11), 12997-13008 [10.1021/acsami.1c02504].
Functionalized Scintillating Nanotubes for Simultaneous Radio- and Photodynamic Therapy of Cancer
Villa, IreneCo-primo
;Crapanzano, Roberta;Secchi, Valeria;Tawfilas, Massimo;Campione, Marcello;Vedda, Anna;Monguzzi, Angelo
Ultimo
2021
Abstract
As a model radio-photodynamic therapy (RPDT) agent, we developed a multicomponent nanomaterial by anchoring conjugated chromophores on the surface of scintillating chrysotile nanotubes. Its ultimate composition makes the system a scintillation-activated photosensitizer for the singlet oxygen production. This nanomaterial shows a remarkable ability to enhance the production of singlet oxygen in an aqueous environment, under X-ray irradiation, boosting its production by almost 1 order of magnitude. Its efficiency as a coadjutant for radiotherapy has been tested in vitro, showing a striking efficacy in enhancing both the prompt cytotoxicity of the ionizing radiation and the long-term cytotoxicity given by radiation-activated apoptosis. Notably, the beneficial activity of the RPDT agent is prominent at low levels of delivered doses comparable to the one employed in clinical treatments. This opens the possibility of effectively reducing the therapy exposure and consequently undesired collateral effects due to prolonged exposure of patients to high-energy radiation.File | Dimensione | Formato | |
---|---|---|---|
[P71]_acsami.1c02504.pdf
Accesso Aperto
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Dimensione
6.59 MB
Formato
Adobe PDF
|
6.59 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.